Merck KGaA Bets $11.3 Billion on Bio-Techne and the Tools That Build Tomorrow’s Drugs
Germany's Merck KGaA is paying $11.3 billion for Minneapolis-based Bio-Techne Corp., a 36% premium that marks its biggest acquisition since Sigma-Aldrich a decade ago. The all-cash deal bets that platforms powering cell

Follow